Exelixis, Inc. (EXEL)

Market Cap	11.56B
Revenue (ttm)	2.30B
Net Income (ttm)	643.57M
Shares Out	272.71M
EPS (ttm)	2.20
PE Ratio	19.24
Forward PE	17.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,940,079
Open	42.71
Previous Close	42.86
Day's Range	42.16 - 43.09
52-Week Range	20.14 - 48.85
Beta	0.25
Analysts	Buy
Price Target	38.76 (-8.56%)
Earnings Date	May 13, 2025

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 1,147
• Stock Exchange: NASDAQ
• Ticker Symbol: EXEL
• Website: https://www.exelixis.com

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Analyst Forecast

According to 18 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is $38.76, which is a decrease of -8.56% from the latest price.

Price Target

$38.76

(-8.56% downside)

Analyst Consensus: Buy